Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Heba Youssef: Off-Label Doesn’t Mean Off-Guidelines
Heba Youssef/LinkedIn
Aug 9, 2026, 08:29

Heba Youssef: Off-Label Doesn’t Mean Off-Guidelines

Heba Youssef, Clinical Nutrition Pharmacist at Helwan General Hospital, shared a post on LinkedIn about a recent article by Adam Cuker et al., published in Blood Advances, adding:

“Off-label doesn’t mean off-guidelines.

I was following a HIT case recently, and the same question kept surfacing: do we wait and manage cautiously, or move before thrombosis has a chance to develop?

Apixaban was part of the answer – but only if we follow the protocol correctly from the very first dose.

The initial dose is 10 mg twice daily, continued for 7 days or until platelet recovery, whichever is longer. After that, we transition to the maintenance dose of 5 mg twice daily.

The part that’s easy to overlook is the switch from a non-heparin parenteral anticoagulant: if the patient has completed greater than or equal to 7 days and platelets have recovered, we can start directly at 5 mg.

But if it’s been less than 7 days, we continue 10 mg until a total of 7 days of non-heparin anticoagulation is reached, then step down.

In HIT without thrombosis, some experts favor starting at 5 mg from the outset in selected patients – a reminder that this isn’t a one-size-fits-all algorithm.

Duration isn’t fixed either: 4 weeks to 3 months for HIT without thrombosis, extending to 3-6 months when thrombosis is present (HITT).

And the lesson I keep coming back to: DOACs are not first-line in hemodynamically unstable patients or those with life- or limb-threatening thrombosis. In these situations, we start with a parenteral non-heparin anticoagulant first, then consider transitioning.

The pearl I take from every case like this: a protocol isn’t just a set of dosing numbers — it’s a complete decision map that protects the patient at every turning point.”

Title: American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia

Authors: Adam Cuker, Gowthami M. Arepally, Beng H. Chong, Douglas B. Cines, Andreas Greinacher, Yves Gruel, Lori A. Linkins, Stephen B. Rodner, Sixten Selleng, Theodore E. Warkentin, Ashleigh Wex, Reem A. Mustafa, Rebecca L. Morgan, Nancy Santesso

Heba Youssef: Off-Label Doesn't Mean Off-Guidelines

Stay updated with Hemostasis Today.

Adam Cuker Andreas Greinacher Ashleigh Wex Beng H. Chong Blood Advances Douglas B Cines Gowthami M. Arepally Guidelines Health Heba Youssef Hematology Hemostasis Hemostasis News Hemostasis Today Lori A. Linkins Medicine Nancy Santesso Rebecca L. Morgan Reem A. Mustafa Sixten Selleng Stephen B. Rodner Theodore E. Warkentin Yves Gruel
NewsFeed